WO1996005190A1 - 3-benzoyl benzofuran derivatives as thyroid hormone antagonists - Google Patents

3-benzoyl benzofuran derivatives as thyroid hormone antagonists Download PDF

Info

Publication number
WO1996005190A1
WO1996005190A1 PCT/EP1995/003214 EP9503214W WO9605190A1 WO 1996005190 A1 WO1996005190 A1 WO 1996005190A1 EP 9503214 W EP9503214 W EP 9503214W WO 9605190 A1 WO9605190 A1 WO 9605190A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxymethoxybenzoyl
diiodo
benzofuran
butyl
isopropyl
Prior art date
Application number
PCT/EP1995/003214
Other languages
English (en)
French (fr)
Inventor
Charlotta Mellin
Original Assignee
Karo Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio Ab filed Critical Karo Bio Ab
Priority to US08/776,924 priority Critical patent/US5854282A/en
Priority to DK95929866T priority patent/DK0775129T3/da
Priority to DE69505542T priority patent/DE69505542T2/de
Priority to JP8507025A priority patent/JPH10504297A/ja
Priority to EP95929866A priority patent/EP0775129B1/de
Priority to AU33455/95A priority patent/AU694551B2/en
Priority to KR1019970700890A priority patent/KR970704725A/ko
Publication of WO1996005190A1 publication Critical patent/WO1996005190A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to organic compounds which function as nuclear receptor ligands and
  • thyroid hormone antagonists particularly as thyroid hormone antagonists.
  • thyroid hormones bind to nuclear thyroid hormone receptors.
  • the complex formed by the thyroid hormone and the nuclear receptor binds to particular
  • thyroid responsive elements DNA patterns, termed “thyroid responsive elements” (TRE) in the promoter region of TRE
  • T-3)-regulated genes 3,5,3'- triiodothyronine (T-3)-regulated genes.
  • the genes may be positively or negatively
  • T3 that is to say as thyroid hormone antagonists.
  • R' C M alkyl
  • R 2 -NHSO 2 R 3 ; NHCOR 3 ; or -NHCONHR 3
  • the compound may be selected from 2-n-Butyl-3(3,5-diiodo-4-
  • the compound is preferably 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • the compounds of the present invention have an equal or better receptor binding affinity
  • the compounds of the present invention may be used in the treatment of disorders which are described
  • T-3 -regulated genes for example, heart arrhythymia
  • a patient with a T-3-regulated gene disorder comprising administering a compound
  • the disorder may be for example, heart
  • arrythymia heart failure, or hyperthyroidism.
  • Fig. 1 is a T3 dose response curve in TRAF o cells
  • Fig. 2 illustrates the effects of 2-n-Buty 1-3(3 ,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 3 illustrates the effects of 2-n-butyl-3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 4 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 5 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4- hydroxybenzamido)benzofuran on TRAF ⁇ cells;
  • Fig. 6 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzyl)-5-
  • Fig. 7 illustrates the effects of 2-isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 8 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 9 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 10 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 11 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 12 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 13 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4- hydroxyphenylureido)benzofuran on TRAF ⁇ cells;
  • Fig. 14 illustrates the effects of 2-n-Butyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-(4- hydroxybenzamido)benzofuran on TRAF ⁇ cells;
  • Fig. 15 illustrates the effects of 2-Isopropyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-
  • Fig. 16 illustrates the effects of 2-Isopropyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-
  • Fig. 17 is a T3 dose response curve in TRAF ⁇ cells
  • Fig. 18 illustrates the effects of 2-n-Butyl-3(3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 19 illustrates the effects of 2-n-butyl-3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 20 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 21 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 22 illustrates the effects of
  • Fig. 23 illustrates the effects of 2-isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 24 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 25 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 26 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 27 illustrates the effects of 2-Isopropyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 28 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4- methoxyphenylureido)benzofuran on TRAF ⁇ cells;
  • Fig. 29 illustrates the effects of 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 30 illustrates the effects of 2-n-Butyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-(4-
  • Fig. 31 illustrates the effects of 2-Isopropyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-
  • Fig. 32 illustrates the effects of 2-Isopropyl-3-(3,5-dibromo-4-carboxymethoxybenzoyl)-5-
  • Fig. 33 illustrates competition between 2-n-Butyl-3(3,5-diiodo-4-carboxymethoxybenzoyl)-
  • Fig. 34 illustrates competition between 2-n-butyl-3,5-diiodo-4-carboxymethoxybenzoyl)-5-
  • Fig. 35 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-
  • Fig. 36 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-
  • Fig. 37 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxy
  • Fig. 38 illustrates the competition between 2-isopropyl-3-(3,5-diiodo-4-
  • Fig. 39 illustrates the competition between 2-Isopropyl-3-(3,5-diiodo-4-
  • Fig. 40 illustrates competition between 2-Isopropyl-3-(3,5-diiodo-4- carboxymethoxybenzoyl)-5-(4-hydroxybenzamido)benzofuran and 12S I-T 3 for binding to
  • Fig. 41 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-
  • Fig. 42 illustrates competition between 2-Isopropyl-3-(3,5-diiodo-4- carboxymethoxybenzoyl)-5-(4-nitrobenzamido)benzofuran and 125 I-T*, for binding to ThR ⁇ l ;
  • Fig. 43 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)-
  • Fig. 44 illustrates competition between 2-n-Butyl-3-(3,5-diiodo-4-carboxymethoxybenzoyl)- 5-(4- hydroxyphenylureido)benzofuran and 125 I-T 3 for binding to ThR ⁇ l;
  • Fig. 45 illustrates competition between 2-n-Butyl-3-(3,5-dibromo-4-
  • Fig. 46 illustrates competition between 2-Isopropyl-3-(3,5-dibromo-4-
  • Fig. 47 illustrates competition between 2-Isopropyl-3-(3,5-dibromo-4-
  • Triethylamine (15 ml) was added and the solution was refluxed for 3h. The
  • reaction mixture was diluted with ethyl acetate and washed with water and brine.
  • Example 1(g) 70 mg, 0.11 mmol was treated with 4-fluorobenzoyl chloride by
  • the thyroid hormone reporter cell lines (TRAF ⁇ and TRAF ⁇ ) are genetically engineered,
  • thyroid hormone receptor (ThR) ⁇ and ⁇ , respectively.
  • TRE thyroid hormone response element
  • ALP alkaline phosphatase
  • the ThR is activated resulting in transcriptional activation of the
  • ALP reporter gene mediated through the TRE.
  • AMPPD sodium 3-4-methoxyspiro(l,2-dioxetane-3,2'-
  • AMPPD was purchased from Boule Diagnostic, Sweden.
  • the cells have to
  • T3 3,5,3'-triodothyronine
  • the ALP reporter gene i.e. their agonistic/antagonistic activity.
  • the TRAF ⁇ and ⁇ cells were seeded at a density of 2-2.5 x 10 4 cells/well in
  • Coon's medium (without phenolred) (SVA, Uppsala, Sweden) + 10% FCS (Gibco-BRL)
  • test for agonist activity in the absence of T3 addition :
  • concentration range (example 1-3, 5): from 10 "9 to 10 s M test compound as indicated on the x-axis, vehicle only (no test compound added) appears as 10 10 M on the x-axis;
  • concentration range (example 4): from 10 8 to 4xlO "5 M test compound as indicated on the
  • concentration range (example 6): from 10 "7 to 4xlO "5 M test compound as indicated on the
  • concentration range (example 7-10: from 5xl0 "9 to 2xlO '5 M test compound as indicated on
  • concentration range (example 11-14): from 10 "7 to 3.2xlO "5 M test compound as indicated
  • concentration range (example 15): from 10 "7 to 6.4xl0 5 M test compound as indicated on
  • concentration range (example 1-3, 5): from 10 9 to 10 s M test compound as indicated on the
  • concentration range (example 4): from 10 8 to 4xlO "5 M test compound as indicated on the x-axis in the presence of 1 nM T3, vehicle and InM T3 only (no test compound added)
  • concentration range (example 6): from 10 "7 to 4xlO "5 M test compound as indicated on the
  • concentration range (example 7-10): from 5xl0 "9 to 2xl0 5 M test compound as indicated on
  • concentration range (example 11-14): from 10 "7 to 3.2xl0 5 M test compound as indicated
  • concentration range (example 15): from 10" 7 to 6.4xlO' 5 M test compound as indicated on
  • the range of affinities for the ThR ⁇ l is between 10 "5 10 M. to 10 "5 9O M.
  • ThR ⁇ l are relatively small.
  • ThR ⁇ and ⁇ reporter cell lines Two compounds (example 14 and 15) had a partial

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/EP1995/003214 1994-08-11 1995-08-11 3-benzoyl benzofuran derivatives as thyroid hormone antagonists WO1996005190A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US08/776,924 US5854282A (en) 1994-08-11 1995-08-11 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
DK95929866T DK0775129T3 (da) 1994-08-11 1995-08-11 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
DE69505542T DE69505542T2 (de) 1994-08-11 1995-08-11 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
JP8507025A JPH10504297A (ja) 1994-08-11 1995-08-11 甲状腺ホルモンアンタゴニストとしての３−ベンゾイルベンゾフラン誘導体
EP95929866A EP0775129B1 (de) 1994-08-11 1995-08-11 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
AU33455/95A AU694551B2 (en) 1994-08-11 1995-08-11 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
KR1019970700890A KR970704725A (ko) 1994-08-11 1995-08-11 수용체 리간드

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9416219.5 1994-08-11
GB9416219A GB9416219D0 (en) 1994-08-11 1994-08-11 Receptor ligands

Publications (1)

Publication Number Publication Date
WO1996005190A1 true WO1996005190A1 (en) 1996-02-22

Family

ID=10759723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003214 WO1996005190A1 (en) 1994-08-11 1995-08-11 3-benzoyl benzofuran derivatives as thyroid hormone antagonists

Country Status (12)

Country Link
US (1) US5854282A (de)
EP (1) EP0775129B1 (de)
JP (1) JPH10504297A (de)
KR (1) KR970704725A (de)
AT (1) ATE172460T1 (de)
AU (1) AU694551B2 (de)
CA (1) CA2197185A1 (de)
DE (1) DE69505542T2 (de)
DK (1) DK0775129T3 (de)
ES (1) ES2123287T3 (de)
GB (1) GB9416219D0 (de)
WO (1) WO1996005190A1 (de)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058519A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1116719A2 (de) * 2000-01-17 2001-07-18 Clariant (France) S.A. 3-(1-Hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-on, ein Verfahren zu seiner Herstellung und seine Verwendung
WO2001098256A1 (en) * 2000-06-21 2001-12-27 Karo Bio Ab Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
FR2817864A1 (fr) * 2000-12-11 2002-06-14 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
WO2003009839A1 (en) * 2001-07-20 2003-02-06 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
FR2864536A1 (fr) * 2003-12-24 2005-07-01 Clariant France Sa Procede de preparation de n-alkyl-2 (hydroxy-4-benzoyl)-3 benzofurannes et intermediaires pour sa mise en oeuvre
WO2008001959A1 (fr) 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Nouveau dérivé hétérocyclique 6-5 bicyclique et utilisation médicale de celui-ci
FR2914644A1 (fr) * 2007-04-06 2008-10-10 Finorga Soc Par Actions Simpli Procede de preparation de 2-(n-butyl)-3-(4-hydroxybenzoyl) -5-nitrobenzofurane
FR2914643A1 (fr) * 2007-04-06 2008-10-10 Finorga Soc Par Actions Simpli Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane
FR2915482A1 (fr) * 2007-04-27 2008-10-31 Finorga Soc Par Actions Simpli Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane.
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
CN101948455A (zh) * 2010-10-18 2011-01-19 山东邹平大展新材料有限公司 一种2-正丁基-3-(4-羟基苯甲酰基)-5-硝基苯并呋喃的制备方法
US8658809B2 (en) 2010-01-08 2014-02-25 Sanofi Process for the preparation of dronedarone
US9174958B2 (en) 2010-06-18 2015-11-03 Sanofi Process for the preparation of dronedarone
US9174959B2 (en) 2011-03-29 2015-11-03 Sanofi Process for preparation of dronedarone by N-butylation
US9193703B2 (en) 2011-03-29 2015-11-24 Sanofi Process for preparation of dronedarone by mesylation
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9221777B2 (en) 2012-01-20 2015-12-29 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction
US9249119B2 (en) 2012-02-14 2016-02-02 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9334254B2 (en) 2010-03-30 2016-05-10 Sanofi Process for preparing sulfonamidobenzofuran derivatives
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
US9499507B2 (en) 2011-11-29 2016-11-22 Sanofi Method for preparing 5-amino-benzoyl-benzofuran derivatives
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6317722B1 (en) * 1998-09-18 2001-11-13 Amazon.Com, Inc. Use of electronic shopping carts to generate personal recommendations
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
GB0611210D0 (en) * 2006-06-07 2006-07-19 Cambrex Karlskoga Ab Process
KR100858357B1 (ko) * 2006-10-02 2008-09-11 (주) 디지탈바이오텍 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3342624A1 (de) * 1983-11-25 1984-03-29 Heinfried Dr. 4019 Monheim Grote Benzaronderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
EP0471609A1 (de) * 1990-08-06 1992-02-19 Sanofi Benzofuranderivate, Benzothiophene, Indole oder Indolizine, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen
WO1992020331A1 (en) * 1991-05-17 1992-11-26 Karobio Aktiebolag Receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255585A (en) * 1975-10-22 1981-03-10 Centre European De Recherches Pharmacologique Benzoheterocyclic derivatives of phenoxyacetic acid
US4851554A (en) * 1987-04-06 1989-07-25 University Of Tennessee Research Corporation Certain 3-substituted 2-alkyl benzofuran derivatives
JP2873599B2 (ja) * 1990-03-09 1999-03-24 寿製薬株式会社 新規ベンゾフラン誘導体、尿酸排泄剤及びその製法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3342624A1 (de) * 1983-11-25 1984-03-29 Heinfried Dr. 4019 Monheim Grote Benzaronderivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel
EP0471609A1 (de) * 1990-08-06 1992-02-19 Sanofi Benzofuranderivate, Benzothiophene, Indole oder Indolizine, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen
WO1992020331A1 (en) * 1991-05-17 1992-11-26 Karobio Aktiebolag Receptor ligands

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058519A1 (en) * 1998-05-12 1999-11-18 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6515147B2 (en) 2000-01-17 2003-02-04 Clariant France S.A. 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one a process for the preparation thereof and the use thereof
EP1116719A3 (de) * 2000-01-17 2001-10-24 Clariant (France) S.A. 3-(1-Hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-on, ein Verfahren zu seiner Herstellung und seine Verwendung
USRE39755E1 (en) 2000-01-17 2007-07-31 Clariant France 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one a process for the preparation thereof and the use thereof
EP1116719A2 (de) * 2000-01-17 2001-07-18 Clariant (France) S.A. 3-(1-Hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-on, ein Verfahren zu seiner Herstellung und seine Verwendung
FR2803846A1 (fr) * 2000-01-17 2001-07-20 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
AU779880B2 (en) * 2000-06-21 2005-02-17 Karo Bio Ab Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
WO2001098256A1 (en) * 2000-06-21 2001-12-27 Karo Bio Ab Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
US7199265B2 (en) 2000-06-21 2007-04-03 Karo Bio Ab Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
CZ303488B6 (cs) * 2000-12-11 2012-10-17 Sanofi-Aventis Methansulfonamidobenzofuran, zpusob jeho prípravy a jeho použití jako syntetického meziproduktu
US6828448B2 (en) 2000-12-11 2004-12-07 Sanofi-Synthelabo Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
WO2002048132A1 (fr) * 2000-12-11 2002-06-20 Sanofi-Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817864A1 (fr) * 2000-12-11 2002-06-14 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
WO2003009839A1 (en) * 2001-07-20 2003-02-06 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
FR2864536A1 (fr) * 2003-12-24 2005-07-01 Clariant France Sa Procede de preparation de n-alkyl-2 (hydroxy-4-benzoyl)-3 benzofurannes et intermediaires pour sa mise en oeuvre
WO2005066149A1 (en) * 2003-12-24 2005-07-21 Clariant (France) Process for the preperation of n-alkyl-2(hydroxy-4 benzoyl)-3 benzofurans and its intermediates thereof
CN101486698B (zh) * 2003-12-24 2011-07-27 克拉里安特专业精细化学（法国）公司 取代的苯并呋喃及其制备方法
US10925885B2 (en) 2005-05-26 2021-02-23 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2008001959A1 (fr) 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Nouveau dérivé hétérocyclique 6-5 bicyclique et utilisation médicale de celui-ci
FR2914644A1 (fr) * 2007-04-06 2008-10-10 Finorga Soc Par Actions Simpli Procede de preparation de 2-(n-butyl)-3-(4-hydroxybenzoyl) -5-nitrobenzofurane
FR2914643A1 (fr) * 2007-04-06 2008-10-10 Finorga Soc Par Actions Simpli Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane
WO2008139057A2 (fr) * 2007-04-06 2008-11-20 Finorga Procede de preparation de 2-(n-butyl)-3-(4-hydroxybenzoyl)-5-nitrobenzofurane
WO2008139056A1 (fr) * 2007-04-06 2008-11-20 Finorga Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane
WO2008139057A3 (fr) * 2007-04-06 2009-01-08 Finorga Procede de preparation de 2-(n-butyl)-3-(4-hydroxybenzoyl)-5-nitrobenzofurane
WO2008152217A3 (fr) * 2007-04-27 2009-02-26 Finorga Procede de preparation du 2-(n-butyu-5-nitrobenzofurane
FR2915482A1 (fr) * 2007-04-27 2008-10-31 Finorga Soc Par Actions Simpli Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane.
WO2008152217A2 (fr) * 2007-04-27 2008-12-18 Finorga Procede de preparation du 2-(n-butyu-5-nitrobenzofurane
US8658809B2 (en) 2010-01-08 2014-02-25 Sanofi Process for the preparation of dronedarone
US9334254B2 (en) 2010-03-30 2016-05-10 Sanofi Process for preparing sulfonamidobenzofuran derivatives
US9174958B2 (en) 2010-06-18 2015-11-03 Sanofi Process for the preparation of dronedarone
CN101948455B (zh) * 2010-10-18 2012-11-14 山东邹平大展新材料有限公司 一种2-正丁基-3-(4-羟基苯甲酰基)-5-硝基苯并呋喃的制备方法
CN101948455A (zh) * 2010-10-18 2011-01-19 山东邹平大展新材料有限公司 一种2-正丁基-3-(4-羟基苯甲酰基)-5-硝基苯并呋喃的制备方法
US9193703B2 (en) 2011-03-29 2015-11-24 Sanofi Process for preparation of dronedarone by mesylation
US9611242B2 (en) 2011-03-29 2017-04-04 Sanofi Process for preparation of dronedarone by N-butylation
US9174959B2 (en) 2011-03-29 2015-11-03 Sanofi Process for preparation of dronedarone by N-butylation
US9499507B2 (en) 2011-11-29 2016-11-22 Sanofi Method for preparing 5-amino-benzoyl-benzofuran derivatives
US9221777B2 (en) 2012-01-20 2015-12-29 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9708281B2 (en) 2012-01-20 2017-07-18 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9701654B2 (en) 2012-02-13 2017-07-11 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
US9249119B2 (en) 2012-02-14 2016-02-02 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
US9382223B2 (en) 2012-02-22 2016-07-05 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
US9238636B2 (en) 2012-05-31 2016-01-19 Sanofi Process for preparation of dronedarone by Grignard reaction
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Also Published As

Publication number Publication date
KR970704725A (ko) 1997-09-06
DK0775129T3 (da) 1999-06-28
CA2197185A1 (en) 1996-02-22
AU3345595A (en) 1996-03-07
DE69505542D1 (de) 1998-11-26
GB9416219D0 (en) 1994-10-05
JPH10504297A (ja) 1998-04-28
AU694551B2 (en) 1998-07-23
US5854282A (en) 1998-12-29
EP0775129B1 (de) 1998-10-21
ES2123287T3 (es) 1999-01-01
DE69505542T2 (de) 1999-06-02
ATE172460T1 (de) 1998-11-15
EP0775129A1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
AU694551B2 (en) 3-benzoyl benzofuran derivatives as thyroid hormone antagonists
ES2312333T3 (es) Adn que codifica un receptor snorf25.
US5219548A (en) High affinity halogenated-tamoxifen derivatives and uses thereof
Forte et al. Escherichia coli enterotoxin receptors: localization in opossum kidney, intestine, and testis
EP0119955B1 (de) Gewisse 3-(5-Aminopentyl)-amino-1-benzazepin-2-on-1-alkansäuren, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Verwendung
US5122361A (en) Dopamine receptor ligands and imaging agents
Snowdowne et al. Effects of low extracellular sodium on cytosolic ionized calcium. Na+-Ca2+ exchange as a major calcium influx pathway in kidney cells.
HATTORI et al. Metabolism of Magnolol from Magnoliae Cortex. II.: Absorption, Metabolism and Excretion of [ring-14C] Magnolol in Rats
Kobayashi et al. Ca-antagonistic substance from soft coral of the genus Sarcophyton
US4731470A (en) [(5,6-dichloro-3-oxo-2,9a-alkano-2,3,9,9a-tetrahydro-1H-fluoren-7-yl)oxy]alkanoic acids and alkanimidamides
DE60220179T2 (de) Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
US5690906A (en) Dopamine D-3 and serotonin (5-HT1A) receptor ligands and imaging agents
DE3728810C2 (de) In 3-Stellung tritiummarkierte 2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo-[b]-thiophencarbonsäure, Verfahren zu ihrer Herstellung und ihre Verwendung
AU660681B2 (en) Receptor ligands
Takei et al. Intracellular storage and evoked release of acetylcholine from postnatal rat basal forebrain cholinergic neurons in culture with nerve growth factor
Azzi et al. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists
US5958927A (en) Indanol compounds
Emala et al. Expression of muscarinic receptor subtypes and M2-muscarinic inhibition of adenylyl cyclase in lung
Terjung et al. Effect of exercise on the turnover of cytochrome c in skeletal muscle
US5186921A (en) Dopamine receptor ligands and image agents
Raber et al. Co-ordinated control of apical calcium influx and basolateral calcium efflux in rabbit cortical collecting system
Dikranian et al. Increase in immunoreactivity to endothelin-1 in the mucosal vasculature and epithelium of the large intestine during chronic hypoxia.
US4883649A (en) Iodinated clonidine derivatives as radioactive imaging tracers
McPherson et al. Biliary excretion and metabolism of14C cimetidine following oral administration to male and female rats
Noble et al. Prednisone‐neostigmine interactions at cholinergic junctions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2197185

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019970700890

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995929866

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08776924

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995929866

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970700890

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1995929866

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970700890

Country of ref document: KR